Background: Obstructive Sleep Apnea (OSA) is a prevalent long-term condition that has important metabolic effects. Through weight loss, better glycemic management, and other mechanisms, tirzepatide, a dual GLP-1 and GIP receptor agonist, has been demonstrated to be useful in controlling OSA. Objective: The purpose of this review was to explore the impact and potential of tirzepatide in OSA management, including clinical evidence, advantages over the current therapy and future applications. Methods: A comprehensive review of recent clinical trials, literature including SURMOUNT OSA and mechanistic studies. Results: Tirzepatide significantly reduces the Apnea-Hypopnea Index (AHI) which is a measuring parameter of OSA, improves metabolic parameters, and offers a treatment option for patients who cannot adhere to the traditional standard therapy. Conclusion: Tirzepatide represents a breakthrough in OSA treatment, warranting further exploration in long-term trials.